Last edited by Tauzilkree
Friday, July 31, 2020 | History

3 edition of Myocardial protection and cardioplegia found in the catalog.

Myocardial protection and cardioplegia

Myocardial protection and cardioplegia

proceedings of the satellite symposium

  • 208 Want to read
  • 37 Currently reading

Published by Ishiyaku EuroAmerica in St. Louis .
Written in English

    Subjects:
  • Coronary heart disease -- Surgery -- Congresses.,
  • Cardiac arrest, Induced -- Congresses.,
  • Heart -- Preservation -- Congresses.,
  • Coronary heart disease -- Prevention -- Congresses.,
  • Coronary Disease -- prevention & control -- congresses.,
  • Heart Arrest, Induced -- congresses.,
  • Heart Surgery -- methods -- congresses.

  • Edition Notes

    Bibliography: p. 57-60.

    Statement45th Annual Convention of the Japanese Circulation Society, Tokyo, Japan ; edited by Akio Suzuki, Tei Haku.
    ContributionsSuzuki, Akio, 1929-, Haku, Tei, 1923-, Nihon Junkanki Gakkai. Gakujutsu Shūkai
    Classifications
    LC ClassificationsRD598 .M92 1985
    The Physical Object
    Paginationix, 60 p. :
    Number of Pages60
    ID Numbers
    Open LibraryOL2554974M
    ISBN 100912791209
    LC Control Number85060900

    Download Citation | Myocardial Protection in Children | The combination of hypothermia and potassium-based cardioplegic arrest has become the most common method of myocardial protection in the. The best myocardial protection occurred after retrograde/antegrade cardioplegia; myocardial cooling was homogeneous, left ventricular and right ventricular global function recovered completely (

    Quest Myocardial Protection System 2 The Quest Myocardial Protection System, consisting of the MPS Console and the MPS Delivery Set used together, is intended for use by perfusionists and physicians to deliver whole blood (from any arterial source) and / or cardioplegia . COVID Resources. Reliable information about the coronavirus (COVID) is available from the World Health Organization (current situation, international travel).Numerous and frequently-updated resource results are available from this ’s WebJunction has pulled together information and resources to assist library staff as they consider how to handle .

    achieve chemical arrest and myocardial protection without associated myocardial necrosis reported earlier Key paper: Proved why Melrose soln didn’t work – Roe et al. JTCVS. Reported operative mortality of % for patients undergoing potassium-induced arrest as primary form of myocardial protectionFile Size: 5MB. The Use of del Nido Cardioplegia for Myocardial Protection in Isolated Coronary Artery Bypass Surgery Article (PDF Available) in Heart, Lung and Circulation 29(2) .


Share this book
You might also like

Myocardial protection and cardioplegia Download PDF EPUB FB2

“Integrated myocardial protection” is a myocardial protection strategy that includes antegrade and retrograde delivery of cold-blood cardioplegia and warm cardioplegia perfusion for induction and resuscitation.

Hypothermia reduces myocardial oxygen demand and ischemic injury when coronary flow is interrupted; however. Myocardial protection during cardiac operations: decreased morbidity and lower cost with blood cardioplegia and coronary sinus perfusion.

J Thorac Cardiovasc Surg. Cellular protection during myocardial ischemia: the development and characterization of a procedure for the induction of reversible ischemic arrest.

Circulation ; 54 (2): – Melrose, DG, Dreyer, B, Bentall, HH, et al. Elective cardiac arrest. Myocardial Protection Myocardial protection during cardiac surgery has evolved over the years, and the concept of chemical cardioplegia was introduced in Before the popular use of chemical cardioplegia, topical cardiac hypothermia was used.

On the other hand, crystalloid cardioplegia is affordable and simple to deliver, and a single application suffices for adequate arrest.

Results of clinical and experimental studies of myocardial protection using these 2 strategies in paediatric cardiac surgery are : Joaquín Pérez-Andreu, Joaquín Fernández-Doblas, Augusto Sao Avilés, Teresa de la Torre García, Ferrá.

Try the new Google Books. Check out the new look and enjoy easier access to your favorite features A Textbook of Clinical Cardioplegia. Richard M. Engelman method minutes mitochondria mmHg myocardial cells myocardial infarction myocardial ischemia myocardial preservation myocardial protection myocardial temperature myocardium nifedipine.

Myocardial membrane potential at the 4 phases of the cardiac cycle. When extracellular cardioplegia with high K + (20 mmol/l) displaces blood surrounding the myocytes, the cell membrane potential is increased and it depolarizes more readily, i.e.

at a less negative membrane potential. Objective: Myocardial protection with blood cardioplegia during cardiac surgery is increasingly preferred, but few studies have compared the protective effects of crystalloid cardioplegia.

Cardioplegia Temperature The composition of cardioplegia solutions varies considerably; in contrast, myocardial temperature during cardioplegia is almost uniformly reduced to between 10°C and 12°C or less by the infusion of refrigerated cardioplegia and.

These axioms form the foundation for most cardioplegic solutions today. However warm cardioplegia was successfully introduced in by Calafiore and colleagues.

It seems to offer equivalent myocardial protection under the critical condition that the solution must be applied repetitively or continuously to avoid oxygen deficit of the heart. The convenience of most cardioplegic solutions lies in the good myocardial protection—even Author: Alexandro Hoyer, Philipp Kiefer, Michael Borger.

Cardioplegia is an essential component in myocardial protection during aortic cross-clamping and cardiopulmonary bypass. A good understand of the various compositions of cardioplegia, routes of administration, and potential side effects are necessary to reduce morbidity and mortality in patients undergoing cardiac surgery.

Cardiopulmonary Products. Electrosurgical Products. Extracorporeal Life Support (ECLS) Product. Heart Valves Replacement. Transcatheter Aortic. Transcatheter Pulmonary (opens new window) Pediatric Perfusion Products. Revascularization Products (Surgical) Transradial Experience.

Vascular Products. Chronic Total Occlusion Devices. Coronary Stents. Myocardial protection during cardiac surgery aims to preserve myocardial function while providing a bloodless and motionless operating field to make surgery easier. Myocardial protection, since the original reports of Bigelow [1] has been obtained by decreasing myocardial oxygen demand as a consequence of by: The Quest Myocardial Protection System, consisting of the MPS 2 Console and the MPS 2 Delivery Set used together, is intended for use by perfusionists and physicians to deliver whole blood (from any arterial source) and/or cardioplegia solutions to the heart during open heart surgery up to six hours.

Cardioplegic techniques for myocardial protection involve the delivery of cardioplegic solution to the myocardium to provide diastolic electromechanical arrest. This is administered by an anterograde approach via the aortic root or direct coronary ostium access, or by a retrograde manner if severe coronary artery occlusions exist.

Myocardial protection is regarded as one of the most important, yet also most controversial aspects of cardiac surgery. There has been considerable improvement in myocardial protection strategies over recent years, utilising a variety of new approaches to treat cardiac diseases, and this text is intended to embrace the state of the art in this field.

The primary method of myocardial protection during cardiopulmonary bypass (CPB) remains the administration of cardioplegia and the institution of hypothermia. CARDIOPLEGIA Cardioplegia solution composition varies between institutions but is generally composed of a combination of the following.

Custodiol cardioplegia is attractive for minimally invasive cardiac surgery, as a single dose provides a long period of myocardial protection. Despite widespread use in Europe, there is little data confirming its efficacy compared with Cited by: Myocardial protection is regarded as one of the most important, yet also most controversial aspects of cardiac surgery.

There has been considerable improvement in myocardial protection strategies over recent years, utilising a variety of new approaches to treat cardiac diseases, and this text is intended to embrace the state of the art in this book summarises the state.

In the early s, Matte and del Nido 4 developed a novel cardioplegia solution for myocardial protection at the University of Pittsburgh. The upper line reports concepts of myocardial protection, and the lower line reports technologic advances in the delivery of myocardial protection.

Dual-withdrawal delivery refers to the technique of diluting crystalloid cardioplegia solution with blood from the venous reservoir.However, blood cardioplegia produces good myocardial protection, suggesting that the concerns over viscosity and capillary sludging are overstated.

The ideal hematocrit for blood cardioplegia is unknown, but it may depend on the temperature of the myocardium and the frequency of administration.Myocardial protection: the rebirth of potassium-based cardioplegia.

The UCLA School of Medicine, University of California, Los Angeles, by: